The study was performed on 25 patients diagnosed with liver tumors, assigned magnetic resonanceimaging (MRI) with Primovist - a hepatospecific paramagnetic gadolinium-based contrast agent atthe International Medical Center of Hue Central Hospital. The result is as followed: 11 HCCs, 1 biliarytract malignant tumor, 1 hepatic adenoma, 6 metastates, 2 FNH, 1 hepatic AML, 3 hemangiomas. 47lesions in total, including 9 lesions smaller than 1cm, 12 lesions 1-2 cm, 26 lesions larger than 2 cm.All 11 HCCs are hypointense on T1W, hyperintense on T2W, intratumoral high signal on DWI, 9 caseshave typical enhancement pattern on Dynamic phase (arterial enhancement with washout assessed on theportal venous phase), 10 cases have no enhancement on Hepatocellular phase. Metastasis lesions haveperipheral enhancement on both arterial and venous phases, no enhancement on delayed phase due to nothaving hepatic cells. The the biliary tract tumor is pathologically correct, with minor peripheral enhancement30 seconds after injection, gradual centripetal enhancement after 60 and 90 seconds, no enhancementon delayed phase due to not having hepatic cells. 3 cases with hemangiomas are hyperintense on T2WI,similar to blood vessels, hypointense on T1WI, pheripherally enhanced 30 seconds after injection, fullycentripetal fill-in after 90 seconds, non-enhanced on delayed phase (20 minutes) due to not having hepaticcells. 2 cases with FNH have iso- or mildly hyperintense on T1W, isointense on T2W and hypointense onDWI, isointense on hepatocellular phase due to the reservation of hepatic cells.Liver MRI with Primovist is specific for Hepatic cells, playing a critical role in detecting small lesionsand differentiating benign and malignant lesions of the liver, especially those without typical enhancementpattern on Dynamic phase